MedTrace Logo

QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

NCT06715124 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 237

Last updated 2026-03-02

No results posted yet for this study

Summary

Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.

Conditions

Interventions

DRUG

QTX3544

QTX3544 will be administered at protocol defined dose.

COMBINATION_PRODUCT

Cetuximab

Cetuximab will be administered at protocol defined dose.

Sponsors & Collaborators

  • Quanta Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-14
Primary Completion
2027-01-02
Completion
2029-01-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06715124 on ClinicalTrials.gov